PRL and neutropenia: Other than the four adverse events modelled in this study (i.e. weight gain, diabetes, acute EPS and neutropenia), there are other adverse events which might impact on patients’ QALY and cost outcomes, such as tardive dyskinesia, sexual dysfunction, increase in prolactin levels, and agranulocytosis.